• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Can delayed/extended-release methylphenidate allow for once daily evening dosing in ADHD?

Bioengineer by Bioengineer
April 2, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, April 2, 2019–A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration. These positive findings suggest that HLD200 could provide a novel and more flexible alternative to treating attention deficit hyperactivity disorder (ADHD) in children compared to the currently used immediate-release methylphenidate. The design of each study and the intriguing results are reported in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here
) to read the full-text article free on the Journal of Child and Adolescent Psychopharmacology website.

The article is entitled “Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.” Coauthors Bev Incledon, PhD, Ironshore Pharmaceuticals & Development, Inc., (Grand Cayman, Cayman Islands) and colleagues from University of Maryland School of Pharmacy (Baltimore, MD) and Highland Therapeutics, Inc. (Toronto, Canada) set up a series of studies to be able to evaluate different doses of HLD200, the potential impact of taking the drug in a fasted state or following a high-fat evening meal, and the effects, if any, of a low-fat versus a medium-fat breakfast. The authors also evaluated different dosing strategies.

“For many parents whose children with ADHD are very restless and impulsive from the moment they awake, mornings are very difficult before their first dose of medicine starts to work. This new formulation may potentially correct these early morning problems,” says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.

###

About the Journal

Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published bimonthly in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Media Contact
Kathryn Ryan
[email protected]

Original Source

https://home.liebertpub.com/news/can-delayed-extended-release-methylphenidate-allow-for-once-daily-evening-dosing-in-adhd/3532

Related Journal Article

http://dx.doi.org/10.1089/cap.2018.0122

Tags: BehaviorClinical TrialsMedicine/HealthSocial/Behavioral Science
Share12Tweet7Share2ShareShareShare1

Related Posts

EBMT Unveils 2025 Clinical Practice Guidelines for Hematopoietic Cell Transplantation and CAR-T Therapy

October 2, 2025

Childhood Experiences Shape Nurses’ Burnout and Depression

October 2, 2025

Unseen Weight of Solitude: The Impact of Social Withdrawal on the Adolescent Brain

October 2, 2025

Identifying Diabetic Ketoacidosis Risk Factors in Ethiopia

October 2, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    79 shares
    Share 32 Tweet 20
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Topical Cream Alleviates Skin Side Effects of Chemotherapy

Exploring RNA-Protein Interactions: A Pathway to Innovative Cancer and Brain Disease Therapies

Clinical Trial Explores Internal Radiation Therapy for Kidney Cancer Treatment

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.